The number of abortions in the U.S. kept rising in 2024 because of telehealth prescriptions, report finds
Abortion-rights activists holds a signs as they protest outside of the Supreme Court during a rally on March 26, 2024, in Washington. (AP Photo/Jose Luis Magana)
The number of abortions in the U.S. rose again in 2024, with women continuing to find ways to get them despite bans and restrictions in many states, according to a report out Monday.
The latest report from the WeCount project of the Society of Family Planning, which supports abortion access, was released a day before the third anniversary of the U.S. Supreme Court's ruling that overturned Roe v. Wade and ended nearly 50 years of legal abortion nationally for most of pregnancy.
Currently, 12 states are enforcing bans on abortion at all stages of pregnancy, with limited exceptions, and four have bans that kick in at or about six weeks into pregnancy — often before women realize they are pregnant.
While the total number of abortions has risen gradually over those three years, the number has dropped to near zero in some states, while abortions using pills obtained through telehealth appointments have become more common in nearly all states.
Pills are used in the majority of abortions and are also prescribed in person.
The overall number of abortions has risen, but it is below historic highs
The latest survey, released Monday, tallied about 1.1 million abortions nationally last year, or about 95,000 a month. That is up from about 88,000 monthly in 2023 and 80,000 a month between April and December of 2022. WeCount began after Roe was overturned, and the 2022 numbers don't include January through March, when abortions are traditionally at their highest.
The number is still well below the historic peak in the U.S. of nearly 1.6 million a year in the late 1990s.
The Society of Family Planning relies primarily on surveys of abortion providers and uses estimates.
Pills prescribed by telehealth now account for one-fourth of U.S. abortions
WeCount found that in the months before the Dobbs ruling was handed down, about 1 in 20 abortions was accessed by telehealth.
But during the last three months of 2024, it was up to 1 in 4.
The biggest jump over that time came in the middle of 2023, when laws in some Democratic-controlled states took effect with provisions intended to protect medical professionals who use telehealth to prescribe pills to patients in states where abortion is banned or where there are laws restricting telehealth abortion.
WeCount found that about half of the telehealth abortions last year were facilitated by the shield laws. The number of telehealth abortions also grew for those in states without bans.
WeCount is the only nationwide public source of information about the pills prescribed to women in states with bans. One key caveat is that it is not clear how many of the prescriptions result in abortion. Some women may change their minds, access in-person abortion or be seeking pills to save for future use.
The WeCount data could help explain data from a separate survey from the Guttmacher Institute, which found the number of people crossing state lines for abortion declined last year.
Anti-abortion efforts are focused on pills
Anti-abortion efforts are zeroing in on pills, along with barring federal funds for Planned Parenthood and undoing ballot measures that provided for abortion access.
Three states have sued to try to get courts to limit telehealth prescriptions of mifepristone, one of the two drugs usually used in combination for medication abortions. U.S. President Donald Trump's administration last month told a judge it does not believe the states have legal standing to make that case.
The U.S. Supreme Court last year found that anti-abortion doctors and their organizations didn't have standing, either.
Meanwhile, officials in Louisiana are using criminal laws, and there is an effort in Texas to use civil penalties against a New York doctor accused of prescribing abortion pills to women in their states. Louisiana lawmakers have also sent the governor a bill to further restrict access to the pills.
SBA Pro-Life America President Marjorie Dannenfelser said on a call with reporters Monday that it's a priority for her group to keep pushing U.S. Health Secretary Robert F. Kennedy Jr. and other officials to investigate the safety of abortion pills — and to require that they be dispensed only in person.
Geoff Mulvihill, The Associated Press
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBC
27 minutes ago
- CBC
Trump says Israel and Iran have agreed to a ceasefire
Social Sharing U.S. President Donald Trump said Monday on social media that Israel and Iran have agreed to a "complete and total ceasefire," to be phased in over 24 hours. Trump said on Truth Social that the ceasefire would bring an "Official END" to the war, a major change in the hostilities that followed a U.S. strike over the weekend on three Iranian nuclear sites.
Globe and Mail
32 minutes ago
- Globe and Mail
Postoperative Pain Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, and Pipeline Analysis
"Postoperative Pain Pipeline Insight" DelveInsight's, 'Postoperative Pain - Pipeline Insight, 2025' report provides comprehensive insights about 40+ companies and 50+ pipeline drugs in Postoperative Pain pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Postoperative Pain Pipeline constitutes 45+ key companies continuously working towards developing 50+ Postoperative Pain treatment therapies, analyzes DelveInsight. Postoperative Pain Overview: Postoperative or postsurgical pain is defined as pain persisting for more than 3 to 6 months after surgery, differing in nature and location from any pre-surgical pain. It is often associated with neuropathic pain caused by surgical injury to major peripheral nerves. While any surgery can result in persistent postoperative pain (PPP), procedures like inguinal hernia repair and thoracic surgery, leg amputation, and coronary artery bypass surgery are at higher risk due to potential nerve damage. Surgical techniques that minimize nerve injury are critical to reducing this risk. Postoperative pain is categorized as acute (up to 7 days post-surgery) or chronic (lasting over 3 months), arising from cutaneous, deep somatic, or visceral structures. "Postoperative Pain Pipeline Insight 2024" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Postoperative Pain Therapeutics Market. Key Takeaways from the Postoperative Pain Pipeline Report DelveInsight's Postoperative Pain pipeline report depicts a robust space with 45+ active players working to develop 50+ pipeline therapies for Postoperative Pain treatment. In August 2024, Mylan Specialty, LP announced that MR-107A-02 is being evaluated for its safety and efficacy in treating acute pain following herniorrhaphy. In August 2024, Jiangsu HengRui Medicine Co., Ltd. disclosed an ongoing study to assess the safety and effectiveness of bupivacaine liposome injection for local infiltration analgesia in pediatric orthopedic surgeries under real-world conditions. In June 2024, Johnson & Johnson Consumer Inc. announced a study aimed at determining the effectiveness of a fixed-dose combination of acetaminophen and naproxen sodium compared to a placebo in reducing pain over a 48-hour period through multiple doses. In March 2024, Formosa Pharmaceuticals and AimMax Therapeutics received FDA approval for clobetasol propionate ophthalmic suspension 0.05% (APP13007) to treat postoperative inflammation and pain after ocular surgery. Key Postoperative Pain companies such as Vivozon Pharmaceutical Inc., LipoCure, InSitu Biologics, and others are evaluating new drugs for Postoperative Pain to improve the treatment landscape. Promising Postoperative Pain pipeline therapies in various stages of development include VVZ-149, LC-400, INSB-200, and others. Postoperative Pain Pipeline Analysis The report provides insights into: The report provides detailed insights into the key companies that are developing therapies in the Postoperative Pain Market. The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Postoperative Pain treatment. It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Postoperative Pain market. Download our free sample report @ Postoperative Pain Companies There are approx. 45+ key companies which are developing the therapies for Postoperative Pain. The companies which have their Postoperative Pain drug candidates in the most advanced stage, i.e. phase III include, Vivozon Pharmaceutical Inc. DelveInsight's report covers around 22+ products under different phases of clinical development like Late stage products (Phase III) Mid-stage products (Phase II) Early-stage product (Phase I) along with the details of Pre-clinical and Discovery stage candidates Discontinued & Inactive candidates Postoperative Pain pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Intravenous Subcutaneous Oral Intramuscular Tropical Postoperative Pain Products have been categorized under various Molecule types such as Monoclonal Antibody Peptides Polymer Small molecule Gene therapy Download Sample Pages to Get an in-depth Assessment of the Emerging Postoperative Pain Therapies and Key Companies: Postoperative Pain Clinical Trials and advancements Postoperative Pain Pipeline Therapeutic Assessment • Postoperative Pain Assessment by Product Type • Postoperative Pain By Stage • Postoperative Pain Assessment by Route of Administration • Postoperative Pain Assessment by Molecule Type Download Postoperative Pain Sample report to know in detail about the Postoperative Pain treatment market @ Postoperative Pain Therapeutic Assessment Table of Content 1. Report Introduction 2. Executive Summary 3. Postoperative Pain Current Treatment Patterns 4. Postoperative Pain - DelveInsight's Analytical Perspective 5. Therapeutic Assessment 6. Postoperative Pain Late-Stage Products (Phase-III) 7. Postoperative Pain Mid-Stage Products (Phase-II) 8. Early Stage Products (Phase-I) 9. Pre-clinical Products and Discovery Stage Products 10. Inactive Products 11. Dormant Products 12. Postoperative Pain Discontinued Products 13. Postoperative Pain Product Profiles 14. Postoperative Pain Key Companies 15. Postoperative Pain Key Products 16. Dormant and Discontinued Products 17. Postoperative Pain Unmet Needs 18. Postoperative Pain Future Perspectives 19. Postoperative Pain Analyst Review 20. Appendix 21. Report Methodology Request the Sample PDF to Get Detailed Insights About the Postoperative Pain Pipeline Reports Offerings: Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Kritika Rehani Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: Nevada Country: United States Website:
Globe and Mail
2 hours ago
- Globe and Mail
Bronchiectasis Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Epidemiology, Therapies, Companies by DelveInsight
"Bronchiectasis Treatment Market" Bronchiectasis Companies are Insmed, AstraZeneca, Zambon, Renovion, Haisco Pharmaceutical Group, Chiesi Farmaceutici S.p.A, Armata Pharmaceuticals, Verona Pharma, Sanofi, Regeneron Pharmaceuticals, Boehringer Ingelheim, CSL, and others. (Albany, USA) DelveInsight's ' Bronchiectasis Market Insights, Epidemiology, and Market Forecast – 2034 ' report delivers an in-depth understanding of bronchiectasis, historical and forecasted epidemiology, as well as the bronchiectasis market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. The latest healthcare forecast report provides an in-depth analysis of Bronchiectasis, offering comprehensive insights into the Bronchiectasis revenue trends, prevalence, and treatment landscape. The report delves into key Antiphospholipid Syndrome statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Bronchiectasis therapies. Additionally, we cover the landscape of Bronchiectasis clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Bronchiectasis treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Bronchiectasis space. Key Takeaways from the Bronchiectasis Market Report Bronchiectasis Market Size in the 7MM was ~USD 1,581.2 million in 2023, estimated DelveInsight In November 2024:- Sanofi-A Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab, in Participants With Non-cystic Fibrosis Bronchiectasis. ACT18018 is a multinational, randomized, double-blind, placebo-controlled, parallel-group, Phase 2 study with 3 treatment groups. The purpose of this study is to evaluate efficacy, safety and tolerability with 2 dosing regimens of itepekimab compared with placebo in male and/or female participants with NCFB aged 18 years of age up to 85 years of age (inclusive). In November 2024:- Boehringer Ingelheim- This study is open to adults aged 18 years and older with bronchiectasis. People can join the study if they were previously enrolled in another study with BI 1291583 (1397-0012: Airleafᵀᴹ or 1397-0013 Clairaflyᵀᴹ). The purpose of this study is to find out whether a medicine called BI 1291583 helps people with bronchiectasis, an inflammatory lung condition. The investigators also want to know how well people with this condition can tolerate BI 1291583 in the long term. In November 2024:- Verona Pharma PLC- This study is a randomized, double-blind, placebo-controlled study designed to assess the efficacy and safety of ensifentrine inhalation suspension (3 mg) delivered twice daily via standard jet nebulizer over at least 24 weeks, compared to placebo, in subjects with non-cystic fibrosis bronchiectasis (NCFBE). According to DelveInsight's epidemiology model, in the 7MM, the total diagnosed prevalent cases of NCFB were approximately 1,028,651 in 2023. This number is anticipated to rise during the forecast period (2024-2034), driven by increased awareness and screening, along with advancements in diagnostic techniques. In 2023, the US accounted for the highest number of diagnosed prevalent cases of NCFB, with approximately 380,711 cases, while France accounted for the least, with only 37,576 cases. Among EU4 and the UK, the UK accounted for the highest number of diagnosed prevalent cases of NCFB, with approximately 224,976 cases in 2023, followed by Spain with approximately 149,236 cases, and Italy with nearly 89,584 cases. Among the severity-specific diagnosed prevalent cases of NCFB in EU4 and the UK in 2023, there were approximately 235,481 moderate cases, around 163,649 severe cases, and 152,230 mild cases. Among the gender-specific cases of NCFB in the UK in 2023, there were approximately 130,486 cases for females and around 94,490 cases for males. In Japan in 2023, the majority of etiology-specific diagnosed prevalent cases of NCFB were attributed to other pathogen, accounting for 46,600 cases. In 2023, among the 7MM, Japan had approximately 96,580 diagnosed prevalent cases of NCFB. In 2023, among the 7MM, the US accounted for the highest number of diagnosed prevalent cases of cystic fibrosis bronchiectasis, with approximately 41,566 cases, while Japan accounted for the least, with only 59 cases. Among the gender-specific cases of cystic fibrosis bronchiectasis in EU4 and the UK in 2023, there were approximately 17,081 cases for females and around 18,738 cases for males. Among the age-specific cases of cystic fibrosis bronchiectasis in Japan in 2023, there were approximately 24 cases for children and around 36 cases for adult. In 2023, the majority of etiology-specific diagnosed prevalent cases of cystic fibrosis bronchiectasis in Japan were attributed to Staphylococcus aureus, accounting for 36 cases. The leading Bronchiectasis Companies such as Insmed, AstraZeneca, Zambon, Renovion, Haisco Pharmaceutical Group, Chiesi Farmaceutici S.p.A, Armata Pharmaceuticals, Verona Pharma, Sanofi, Regeneron Pharmaceuticals, Boehringer Ingelheim, CSL, and others. Promising Bronchiectasis Therapies such as CHF6333, Itepekimab (SAR440340), BI 1291583, Aztreonam lysine, HSK31858, RESP302, and others. Stay ahead in the Bronchiectasis Therapeutics Market with DelveInsight's Strategic Report @ Bronchiectasis Market Outlook Bronchiectasis Epidemiology Segmentation in the 7MM Total diagnosed prevalent cases Gender-specific diagnosed prevalent cases Severity-specific diagnosed prevalent cases Etiology-specific diagnosed prevalent cases Microbiology of NCFB patients, Total diagnosed prevalent cases Gender-specific diagnosed prevalent cases Age-specific diagnosed prevalent cases Microbiology of cystic fibrosis bronchiectasis Download the report to understand which factors are driving Bronchiectasis epidemiology trends @ Bronchiectasis Prevalence Bronchiectasis Emerging Drugs Brensocatib: Insmed/AstraZeneca Brensocatib, an oral small-molecule inhibitor targeting dipeptidyl peptidase 1 (DPP1), is being developed by Insmed for the treatment of bronchiectasis, CRSsNP, and other neutrophil-driven conditions. By inhibiting DPP1, brensocatib aims to reduce inflammation by blocking the activation of neutrophil serine proteases (NSPs), such as neutrophil elastase, during neutrophil formation in the bone marrow. Insmed reported positive topline results from the Phase III ASPEN study of brensocatib in patients with bronchiectasis, leading to plans for a New Drug Application (NDA) submission to the US FDA in late 2024. If approved, brensocatib is expected to launch in the US by mid-2025, followed by launches in Europe and Japan in the first half of 2026. In October 2024, Insmed shared positive late-breaking subgroup data from the Phase III ASPEN study of brensocatib for patients with bronchiectasis at the CHEST 2024 Annual Meeting. Furthermore, the EMA approved a Pediatric Investigational Plan for brensocatib in bronchiectasis patients, and brensocatib has gained access to the PRIME scheme and Breakthrough Therapy Designation for adult bronchiectasis patients. Inhaled Colistimethate Sodium (CMS I-neb): Zambon CMS I-neb is an investigational inhaled therapy for adults with bronchiectasis colonized by P. aeruginosa, potentially offering a first-in-class treatment option. It uses colistimethate sodium, a prodrug of colistin, a polymyxin antibiotic targeting aerobic Gram-negative pathogens, including drug-resistant P. aeruginosa. By disrupting the bacterial cell membrane, colistin causes cell death and serves as a last-resort treatment for infections like carbapenem-resistant P. aeruginosa. In September 2024, Zambon released the results of the Phase III PROMIS-I and PROMIS-II studies in The Lancet Respiratory Medicine journal. The Phase III PROMIS-I trial demonstrated a significant reduction in pulmonary exacerbation rates. Although the PROMIS-II trial was terminated early due to the pandemic, pre-pandemic data showed consistency with PROMIS-I outcomes. Zambon is working with regulatory authorities to expedite patient access. The US FDA has granted CMS I-neb Breakthrough Therapy Designation (BTD), as well as QIDP and Fast Track Designation (FTD). FASENRA (benralizumab): AstraZeneca FASENRA (benralizumab) is a monoclonal antibody that targets the IL-5 receptor alpha on eosinophils, facilitating the recruitment of natural killer cells to induce apoptosis, resulting in rapid and near-complete depletion of blood and tissue eosinophils in most patients. FASENRA is currently under investigation for treating adult patients with NCFB associated with eosinophilic inflammation (bronchiectasis + EI). According to FASENRA completed Phase III clinical trials for this indication in April 2024. Bronchiectasis Treatment Market The treatment of bronchiectasis involves several drug classes tailored to manage symptoms, reduce exacerbations, and control underlying inflammation. Antibiotics, both oral and inhaled, are essential for managing chronic bacterial colonization, particularly against pathogens like P. aeruginosa. Macrolides, often used for their anti-inflammatory properties, are beneficial in reducing exacerbation frequency. Bronchodilators, including beta-agonists and anticholinergics, help alleviate airway obstruction, while corticosteroids are used to address inflammation, although their role remains limited due to potential side effects. Mucolytic agents improve mucus clearance, and emerging anti-inflammatory agents targeting neutrophilic inflammation, such as DPP1 inhibitors, represent innovative approaches. Together, these drug classes form a comprehensive yet evolving treatment landscape for bronchiectasis, addressing its multifaceted pathophysiology. Bronchiectasis Market Outlook The market for bronchiectasis is poised for significant growth due to the evolving landscape of pharmacological and non-pharmacological interventions addressing the complex pathophysiology of the disease. Current therapeutic strategies encompass a range of treatment options which includes medications, chest physical therapy, hydration, and in severe cases, oxygen therapy with inhaled antibiotics demonstrating efficacy in managing chronic bacterial infections and reducing exacerbation rates. Emerging therapies, such as Brensocatib, a Dipeptidyl Peptidase 1 (DPP1) inhibitor, and BI 1291583, a cathepsin C inhibitor, target neutrophilic inflammation through distinct mechanisms, thereby offering novel approaches to improve patient outcomes. Bronchiectasis Therapeutics Market Additionally, investigational therapies like CMS I-neb and monoclonal antibodies such as FASENRA and Itepekimab present further options by directly targeting specific inflammatory pathways associated with eosinophilic inflammation. The incorporation of non-pharmacological approaches, particularly Airway Clearance Techniques (ACTs), complements pharmacological regimens, enhancing mucus clearance and preventing infection. However, the market faces challenges, including a lack of consensus guidelines and under-researched therapies like mucolytics and hyperosmolar agents, which may hinder optimal patient management. Scope of the Bronchiectasis Market Report Coverage- 7MM Bronchiectasis Companies- Insmed, AstraZeneca, Zambon, Renovion, Haisco Pharmaceutical Group, Chiesi Farmaceutici S.p.A, Armata Pharmaceuticals, Verona Pharma, Sanofi, Regeneron Pharmaceuticals, Boehringer Ingelheim, CSL, and others. Bronchiectasis Therapies- CHF6333, Itepekimab (SAR440340), BI 1291583, Aztreonam lysine, HSK31858, RESP302, and others. Bronchiectasis Therapeutic Assessment: Bronchiectasis Current marketed and Lipodystrophy Emerging Therapies Bronchiectasis Market Dynamics: Bronchiectasis Market drivers and Bronchiectasis Market Barriers Table of Content 1. Key Insights 2. Report Introduction 3. Market Overview at a Glance 4. Epidemiology and Market Forecast Methodology 5. Executive Summary 6. Key Events 7. Disease Background and Overview 8. Patient Journey 9. Epidemiology and Patient Population 10. Emerging Drugs 11. Bronchiectasis: Market Analysis 12. Key Opinion Leaders' Views 13. SWOT Analysis 14. Unmet Needs 15. Market Access and Reimbursement 16. Appendix 17. DelveInsight Capabilities 18. Disclaimer 19. About DelveInsight About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Ankit Nigam Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Albany State: New York Country: United States Website:
